Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials
2 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy (NCT01144195) | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials | 2009-09-01 |
| XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma (NCT00557713) | Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials | 2007-02-01 |
Track Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials automatically
Every clearance here is in the API, with alerts when new ones post.